摘要
目的评价常规剂量阿托伐他汀联合依折麦布治疗老年非sT段抬高急性冠状动脉综合征（NSTE—ACS）的疗效及安全性。方法120例NSTE—ACS患者随机分为观察组（阿托伐他汀20mg／d和依折麦布10mg／d，n=60）及对照组（阿托伐他汀40mg／d，n=60）。治疗8周检测患者血脂、丙氨酸氨基转移酶（ALT）、磷酸肌酸激酶（CK）水平，并观察8周内心血管事件及相关不良反应的发生率。结果经治疗8周后，2组血清总胆固醇（TC）、低密度脂蛋白胆固醇（LDL—C）、三酰甘油（TG）均明显低于治疗前，2组间比较差异无统计学意义（P〉0．05）。2组心血管事件（再发心绞痛、急性心肌梗死、心源性死亡）发生率差异亦无统计学意义（P〉0．05）。但观察组ALT、CK水平及相关不良反应发生率均低于对照组（P〈0．05）。结论常规剂量阿托伐他汀联合依折麦布治疗老年NSTE—ACS较强化他汀治疗可同等程度地降低血脂水平，心血管事件发生率和强化他汀治疗者相似，且具有更好的安全性。
Objective To evaluate the efficacy and safety of a routine dose of atorvastatin combined with ezetimibe on elderly patients with non - ST segment elevation acute coronary syndrome （ NSTE - ACS）. Methods A total of 120 NSTE -ACS patients were randomly divided into an observation group （20 mg/d atorvastatin andl0 mg/d ezetimibe, n = 60） and a control group （40 mg/d atorvastatin, n = 60）. The levels of plasma lipids, alanine aminotransferase （ALT） and creatine kinase （CK） of two groups were detected after 8 weeks of treatment. Meanwhile, cardiovascular events and related adverse reactions were observed. Results The levels of serum total cholesterol （TC）, low density lipoprotein - cholesterol （ LDL - C）, and triglyceride （TG） were significantly lower 8 weeks after treatment than before treatment （P 〉 0.05 ）. There was no statistical difference as to the incidence of cardiovascular events （ recurrence of angina pectoris, acute myocardial infarc- tion and cardiac death） between two groups （P 〉 0.05 ）. But the levels of ALT and CK and the incidence of related adverse reaction was reduced in the observation group, compared with the control group （P 〈 0.05）. Conclusions A routine dose of atorvastatin combined with ezetimibe can reduce the levels of blood lipids in elderly NSTE - ACS patients to the same ex- tent with strengthened statin therapy, with a similar incidence of cardiovascular events but better safety.
出处
《徐州医学院学报》
CAS
2016年第8期533-535,共3页
Acta Academiae Medicinae Xuzhou
